Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.
Antidepressive Agents, Second-Generation
/ adverse effects
Anxiety
/ drug therapy
Bulimia
/ drug therapy
Delayed-Action Preparations
Depressive Disorder, Major
/ drug therapy
Drug Interactions
Fibromyalgia
/ drug therapy
Humans
Neurocognitive Disorders
/ drug therapy
Randomized Controlled Trials as Topic
Sexual Dysfunction, Physiological
/ drug therapy
Sleep Initiation and Maintenance Disorders
/ drug therapy
Stress Disorders, Post-Traumatic
/ drug therapy
Substance-Related Disorders
/ drug therapy
Trazodone
/ adverse effects
Journal
Rivista di psichiatria
ISSN: 2038-2502
Titre abrégé: Riv Psichiatr
Pays: Italy
ID NLM: 0425672
Informations de publication
Date de publication:
Historique:
entrez:
6
8
2019
pubmed:
6
8
2019
medline:
25
1
2020
Statut:
ppublish
Résumé
To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder. Medline and Cochrane Library searches were searched using the keywords 'trazodone' AND 'depression', to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Related references were cross checked. European and United States prescribing information was reviewed as well. An effort was made to give weight to the information that was most relevant for daily clinical practice. Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects. Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. SSRI), such as insomnia. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation. Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia.
Substances chimiques
Antidepressive Agents, Second-Generation
0
Delayed-Action Preparations
0
Trazodone
YBK48BXK30
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM